ArticleFrontiers in neurology2025
The efficacy and prognosis analysis of short-term spinal cord stimulation in the treatment of zoster-associated pain: a retrospective study.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparative Efficacy of Short-Term Spinal Cord Stimulation for Subacute Zoster-Associated Pain: A Three-Group Propensity Score-Matched Analysis.Pain and therapy · 2026Article
- Magnetic Resonance Imaging-Based Radiomic Signatures for the Diagnosis of Zoster-Associated Pain: A Quantitative Imaging Approach.Pain and therapy · 2026Article
- Home-Based Remote Programming versus Inpatient Programming After Short-Term Spinal Cord Stimulation for Herpes Zoster Neuralgia: A Single-Center Retrospective Cohort Study.Journal of pain research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Zoster-associated pain (ZAP) is the most common and intractable complication in the clinical setting when patients with herpes zoster (HZ) seek medical treatment. Short-term spinal cord stimulation (stSCS) has been validated as an effective means to relieve ZAP. However, in the existing literature, there is a paucity of comprehensive reports elaborating on the risk factors that impact its treatment efficacy. Objective: This study aimed to evaluate the clinical efficacy of stSCS in the treatment of ZAP, and to analyze the risk factors that influence the treatment efficacy. Methods: Clinical data of patients diagnosed with ZAP and who underwent stSCS surgery in the Pain Department of Shanxi Bethune Hospital from January 2020 to December 2023 were collected. A retrospective analysis was performed to evaluate their clinical efficacy. Principal component analysis (PCA) was utilized to screen potential factors influencing the efficacy, and Logistic regression was employed to establish a predictive model. The accuracy of the model was assessed through the Receiver Operating Characteristic (ROC) curve and the C-index. Results: A total of 98 patients were enrolled in this study. After stSCS treatment, the visual analogue scale (VAS) scores of pain were significantly reduced, the sleep quality of patients was improved, and the dosage of analgesic drugs was markedly decreased compared with that before treatment. The results of multivariate Logistic regression analysis indicated that age [odds ratio (OR): 1.175; 95% confidence interval (CI): 1.864-2.584; Conclusion: Our findings suggest that, stSCS effectively relieves ZAP patients' pain, reduces analgesics consumption, improves sleep quality, with low complication rate and high safety. Notably, age, disease course, diabetes mellitus, and pain area size are independent risk factors for its efficacy. The C-index and ROC area, both 0.824, show the prediction model has good accuracy and discriminative power.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.